Dermaval™ inhibits glucose-induced neutrophil elastase activity in healthy subjects

This article was published in the following Dove Press journal:
Nutrition and Dietary Supplements
23 December 2013
Number of times this article has been viewed

Tania Reyes-Izquierdo1
Boris Nemzer2
Ruby Argumedo1
Cynthia Shu1
Zb Pietrzkowski1
1Applied BioClinical Inc., Irvine, CA, 2FutureCeuticals Inc, Momence, IL, USA

Background: Dermaval™ is a composite formulation of various phytochemical-rich plant materials as quantified using high-performance liquid chromatography. This blend exerts inhibitory activity on human neutrophil elastase (HNE). An acute, crossover clinical study was performed to assess the effects of Dermaval on glucose-induced HNE activity in 20 healthy subjects.

Methods: Participants served as their own controls during this 3-day trial. On day 1, all study participants were fasted and given only 300 mL of water. Blood was drawn before treatment and 60 and 120 minutes post treatment. On day 2, participants were fasted, treated with 75 g of glucose, and similarly tested. On day 3, participants consumed a 50 mg serving of Dermaval followed by 75 g of glucose 15 minutes later. HNE concentration and HNE total activity were determined using enzyme-linked immunosorbent assay.

Results: Average values for HNE activity in the control group (day 1) did not change. Treatment with a single dose of glucose (day 2) increased blood HNE activity by 175% over baseline levels ($P=0.005$) during the first 60 minutes. Pretreatment with Dermaval on day 3 prevented the glucose-induced increase in HNE activity ($P=0.005$ at 60 minutes and $P=0.03$ at 120 minutes versus respective day 2 values). Interestingly, ingestion of 75 g of glucose resulted in the same blood glucose levels on days 2 and 3, indicating that ingestion of Dermaval did not affect glucose absorption.

Conclusion: These results suggest that Dermaval acutely inhibits glucose-induced HNE activity. Further investigations are needed to elucidate the direct and/or indirect mechanism of this effect and to verify whether treatment with Dermaval without glucose may acutely affect activity of HNE as well.

Keywords: crossover study, human neutrophil elastase, glucose

Introduction

Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. In humans, there are six elastase genes that encode the structurally similar proteins, elastase 1, 2, 2A, 2B, 3A, and 3B. Elastase 2, ie, human neutrophil elastase [HNE] (EC 3.4.21.37) also known as lysosomal elastase, polymorphonuclear leukocyte elastase, elastase, serine elastase, lysosomal elastase, granulocyte elastase,1 and leukocyte elastase,2–4 hydrolyzes proteins within specialized neutrophil lysosomes and in the extracellular matrix. HNE plays a role in degenerative and inflammatory diseases by proteolysis of collagen IV and elastin in the extracellular matrix. For example, Schmelzer et al5 reported that HNE plays an important role in the degradation of skin elastin in older individuals. In vitro studies have demonstrated that fibroblasts cultured in three-dimensional collagen gels are able to contract these...
gels and that HNE can enhance the contractile process. HNE contributes significantly to ultraviolet-induced elastin damage, which is a critical part of ultraviolet-accelerated aging. Interestingly, fibroblast elastase produced by dermal fibroblasts was also found to play a crucial role in the degradation of skin elastin induced by ultraviolet radiation.

These and similar observations have prompted many groups to search for inhibitors of HNE. Such inhibitors might be useful to reduce inflammation and to modulate the process of skin aging and formation of wrinkles. Several phytochemicals and chemicals are reported to inhibit HNE under various experimental conditions. Hydroxysteribecone A, for example, is reported to inhibit HNE activity in vitro. Components of specific essential oils are also reported to have anti-HNE activity. Ellagic and tannic acids inhibit premature degradation of elastin fibers in vitro, as do quercetin and punicalagin. However, the literature indicates scant evidence of the ability of these and similar phytochemicals to inhibit HNE activity in vivo.

HNE is a potent protease that can degrade most extracellular matrix components and other host proteins, such as clotting factors, complement, and immunoglobulins. The enzyme contributes to a proinflammatory process. HNE activity is under tight control by endogenous inhibitors, such as alpha 1-antitrypsin, secretory leukocyte protease inhibitor, monocye/neutrophil elastase inhibitor, and pre-elafin (also known as skin-derived antileukoprotease, trappin-2, or WAP-3). As reported by Esposito et al., acute hyperglycemia results in an acute proinflammatory reaction characterized by increased levels of cytokines in the blood. Hyperglycemia also causes an acute increase in neutrophils, a major source of neutrophil elastase. Leukocyte elastase levels also correlate with circulating levels of blood glucose. Therefore, we hypothesized that transient hyperglycemia in otherwise healthy volunteers would induce HNE activity in serum.

Dermaval™ (VDF FutureCeuticals, Inc., Momence, IL USA) is a novel proprietary blend of various plant materials rationally designed to include several phytochemicals, including quercetin, punicalagin, and chlorogenic and neochlorogenic acids, in an amount and ratio necessary to inhibit the enzymatic activity of HNE in blood. The current study was designed to measure the acute effect of a single serving of Dermaval on blood levels of HNE specific enzymatic activity in healthy human subjects. Given that standard values for total serum HNE and HNE activity levels are not yet established for humans and hyperglycemia is known to increase proinflammatory cytokine levels, we used a single dose of glucose to increase and generally standardize HNE activity in the blood of young healthy study subjects.

Materials and methods
Clinical study parameters
This study was conducted according to the guidelines set out in the Declaration of Helsinki and all procedures involving human subjects were approved by the institutional review board at Vita Clinical SA (study protocol ABC-13-05-DML-1). All study subjects received a consent form in which they completed health-related questions prior to selection. All subjects were healthy and had not been using any type of medication or supplement for a period of 15 days prior to the start of the study. The inclusion criteria required participants to be aged 25–35 years and to have a body mass index of 18.5–24.9 kg/m². At the time of the study, all participants were free of rhinitis, influenza, or any other symptom of upper respiratory infection. Participants were excluded if they had diabetes mellitus or a known allergy to any of the test ingredients, or if they were using any anti-inflammatory, analgesic, antiallergy, antidepressant medication, or multivitamins. Participants received oral and written information about the experimental procedures, and written consent was obtained before administration of any treatment.

Study description
Ten male and ten female study subjects who had fasted overnight for approximately 12–16 hours and met the aforementioned inclusion criteria were treated at 8 am with placebo, which consisted of an empty capsule on day 1; a single dose of 75 g of glucose in water on day 2; and 50 mg of encapsulated Dermaval followed 15 minutes later by 75 g of glucose in water on day 3. Prior to treatment, blood was collected from the subjects at baseline. Treatment was initiated at 8 am in the morning and continued for 2 hours. Blood was collected at 60 and 120 minutes on days 1 and 2, and at 60 and 120 minutes after the glucose load on day 3. In all cases, subjects fasted for 12 hours prior to the first blood collection. Other than the study materials, patients had no intake by mouth during the study period and remained calm and resting. One hundred milliliters of blood were collected by finger puncture and placed in Safe-T-Fill® lithium-heparin capillary blood collection tubes (Ram Scientific Inc., Yonkers, NY, USA) at baseline. Subsequent samples were collected 60 and 120 minutes after treatment. Glucose was measured using an Accu-Chek® Compact Plus glucometer and Accu-Chek test strips (Roche Diagnostics, Indianapolis, IN, USA). After blood was collected for the HNE assays, the fingers...
were wiped clean and a glucose test was performed on fresh blood. Glucose was read according to the instructions provided by the manufacturer.

Materials
Dermaval is a proprietary formulation of vegetable and fruit components and protected by a provisional patent. The Dermaval tested in this study was provided by FutureCeuticals Inc., (Momence, IL, USA). Punicalagin A and B and chlorogenic acid standards (neochlorogenic acid 3-CQA, chlorogenic acid 5-CQA, cryptochlorogenic acid 4-CQA, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid) were manufactured by PhytoLab (Vestenbergsgreuth, Germany) and purchased from Cerilliant Corporation (Round Rock, TX, USA). Authentic standards of quercetin, kaempferol, isorhamnetin, and rutin (quercetin 3-O-rutinoside) were purchased from Sigma-Aldrich (St Louis, MO, USA), and kaempferol-3-O-rutinoside (nicotifolin) and isorhamnetin 3-O-rutinoside (narcissin) were purchased from Extrasynthese (Genay, France). The ascorbic acid standard was obtained from United States Pharmacopeia (Rockville, MD, USA). Dulbecco’s phosphate-buffered saline, D- (+)-glucose, and water were purchased from Sigma Chemical Company (St Louis, MO, USA). Protein Low Binding microtubes were obtained from Eppendorf (Hauppauge, NY, USA). An RC DC Protein Assay Kit II was purchased from Bio-Rad Inc., (Palo Alto, CA, USA). Empty gelatin capsules were obtained from Capsuline Inc., (Pompano Beach, FL, USA). An InnoZyme™ human neutrophil elastase (EC 3.4.21.37) immunocapture activity assay kit was sourced from Calbiochem® (EMD Millipore Corporation, Billerica, MA, USA) and from Cayman Chemical Company (Ann Arbor, MI, USA). For total HNE detection, ELA2 (EC 3.4.21.37) enzyme-linked immunosorbent assay kits were obtained from Abnova Corporation (Taipei City, Taiwan). Lancets were purchased from Medlance® (Ozorkow, Poland). The placebo treatments consisted of empty gelatin capsules obtained from Capsuline Inc.

Detection and quantification of HNE
Heparin plasma was isolated from collected blood samples by centrifuging at 1,000 × g for 10 minutes. Total HNE was detected using a colorimetric quantitative sandwich enzyme-linked immunosorbent assay kit following the instructions provided in the kit. Final reactions were measured using a spectrophotometer (Molecular Devices, Sunnyvale, CA, USA) and HNE concentrations were determined based on a standard curve as recommended by the manufacturer. Total HNE activity was determined using HNE immunocapture activity assay kits.

Chemical analysis of Dermaval
Punicalagin analysis
The punicalagin content was measured by a modified high-performance liquid chromatography (HPLC) method developed by Seeram et al.²⁰ and Lu et al.³¹ Two milligrams of the punicalagin standard was dissolved in 5 mL of phosphoric acid for a final concentration of 0.5 volume-volume percent (0.5% v/v), sonicated for 8 minutes, cooled to room temperature, and then diluted to 10 mL with phosphoric acid. An aliquot of the prepared standard was transferred to an autosampler vial for HPLC analysis. One gram of the powdered Dermaval sample was dissolved in 25 mL of phosphoric acid (0.5% v/v), sonicated for 8 minutes, cooled to room temperature, and diluted to 50 mL with phosphoric acid (0.5% v/v). The sample was then centrifuged at a relative centrifugal force of 3,900 × g at 4°C for 20 minutes, and the supernatant was analyzed by HPLC on an Agilent 1100 system (Agilent Technologies, Palo Alto, CA, USA), with a photodiode array detector controlled by Chemstation® chromatography software. Samples were eluted through a Zorbax SB-C18 reversed-phase column (5 μm, 4.6 × 150 mm, Agilent Technologies) using mobile phases consisting of 0.5% v/v phosphoric acid (mobile phase A) and methanol (mobile phase B). The gradient system began with 100% of mobile phase A and 0% of mobile phase B (flow rate 1.0 mL per minute), and after injection (10 μL), this was changed to 100% mobile phase B linearly after 20 minutes. After 25 minutes, it was changed again to 100% mobile phase A and 0% mobile phase B over 5 minutes.

Chlorogenic acid analysis
The modified HPLC method for chlorogenic acids developed by Schrader et al. was used for this analysis.²² Two milligrams of each chlorogenic acid standard (neochlorogenic acid 3-CQA, chlorogenic acid 5-CQA, cryptochlorogenic acid 4-CQA, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid) were dissolved in 5 mL of methanol (50% v/v with water). The standard preparation was sonicated for 10 minutes, cooled to room temperature, and diluted to 10 mL with methanol. One gram of the powdered Dermaval sample was diluted in 50 mL of methanol (50% v/v with water), sonicated for 10 minutes, cooled to room temperature, and diluted to 100 mL with methanol. The sample was then filtered using a GHP syringe filter (0.45 μm) prior to HPLC analysis.
analysis, which was performed on an LC-20 HPLC system (Shimadzu, Kyoto, Japan) consisting of a binary pump with a degasser, a refrigerated autosampler, and a photodiode array detector controlled by LabSolutions chromatographic software. The column used was a Luna C18 (2) reversed-phase column (5 μm, 4.6 × 150 mm) from Phenomenex (Torrance, CA, USA). The initial conditions were 95% acetic acid (2% v/v with water) for mobile phase A and 5% acetonitrile for mobile phase B, at a flow rate of 1.0 mL per minute. The chlorogenic acids were detected by monitoring at 325 nm on the photodiode array detector. The mobile phase gradient program changed linearly to 75% mobile phase A over 60 minutes and then changed to the initial condition (95% mobile phase A) over 30 minutes.

**Flavonoid analysis**

Two milligrams of each flavonoid were diluted in 5 mL of methanol, sonicated for one hour at room temperature, and centrifuged at 5,900 rpm prior to immediate HPLC analysis. One gram of the powdered Dermaval sample was dissolved in 50 mL of methanol, sonicated for 10 minutes, cooled to room temperature, and diluted to 100 mL with water. The sample was then filtered using a GHP syringe filter (0.45 μm) prior to analysis. Kaempferol, quercetin, and rutin analyses were performed by the HPLC method on a Waters 2690 separation module (Waters Corporation, Milford, MA, USA) and a Waters 996 photodiode array detector controlled by Waters Empower 2 chromatographic software (Build Number 2154, Database version 6.10.01). The column used was a Luna C18 (2) reversed-phase column (5 μm, 4.6 × 150 mm) from Phenomenex. The initial conditions were 95% acetic acid (2% v/v with water) and 5% acetonitrile, using a flow rate of 1.0 mL per minute (detection at 325 nm). The mobile phase gradient program was changed linearly to 75% mobile phase A over 60 minutes and then changed to the initial condition (95% mobile phase A) over 30 minutes.

**Ascorbic acid analysis**

Two milligrams of ascorbic acid were dissolved in 5 mL of potassium phosphate buffer (0.2 M KH₂PO₄ pH 2.4) and diluted to 10 mL with this buffer. The powdered sample was weighed and added directly into a 50 mL volumetric flask (about 4 mg/mL). Next, 25 mL of potassium phosphate buffer (0.2 M KH₂PO₄, pH 2.4) was added and mixed. The sample was sonicated for 10 minutes, cooled to room temperature, diluted to volume with potassium phosphate buffer, and mixed. The sample was then filtered using a GHP syringe filter (0.45 μm) and transferred to an autosampler vial for analysis. HPLC analysis of ascorbic acid was performed on an Agilent 1100 HPLC system with a refrigerated autosampler and a photodiode array detector controlled by Chemstation® (Agilent Technologies, Santa Clara, CA, USA) chromatography software. The samples were eluted through an Allure organic acids column (5 μm, 4.6 × 150 mm, from Restek Corporation, Bellefonte, PA, USA) under the initial conditions of 100% potassium phosphate buffer (0.2 M KH₂PO₄, pH 2.4) at a flow rate of 1.0 mL per minute with a column temperature of 30°C (detection at 214 nm).

**Statistical analysis**

HNE levels were normalized using time zero as the baseline. Statistical analysis was performed using the commercially available GraphPad® statistical software (Graphpad Software Inc., La Jolla, CA, USA). Descriptive statistics are presented by the mean ± standard error. Plasma HNE levels at 60 and 120 minutes after treatment were compared within the experimental groups with baseline and between experimental groups using a one-way analysis of variance with Tukey’s post hoc analysis when a significant F-ratio was observed. Statistical significance was set at P<0.05.

### Table 1 Major phytochemicals identified in Dermaval™

<table>
<thead>
<tr>
<th>Active assay</th>
<th>Amount (mg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Punicalagins</td>
<td>202.26</td>
</tr>
<tr>
<td>Chlorogenic acids total</td>
<td>15.51</td>
</tr>
<tr>
<td>Neochlorogenic acid (3-CQA)</td>
<td>2.01</td>
</tr>
<tr>
<td>Chlorogenic acid (5-CQA)</td>
<td>7.69</td>
</tr>
<tr>
<td>Cryptochlorogenic acid (4-CQA)</td>
<td>2.28</td>
</tr>
<tr>
<td>5-Feruloyquinic acid (5-FQA)</td>
<td>1.59</td>
</tr>
<tr>
<td>3,4-dicaffeoylquinic acid (3,4-diCQA)</td>
<td>0.61</td>
</tr>
<tr>
<td>3,5-dicaffeoylquinic acid (3,5-diCQA)</td>
<td>0.51</td>
</tr>
<tr>
<td>4,5-dicaffeoylquinic acid (4,5-diCQA)</td>
<td>0.82</td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td>8.71</td>
</tr>
<tr>
<td>Quercetin</td>
<td>13.98</td>
</tr>
<tr>
<td>Rutin</td>
<td>0.34</td>
</tr>
<tr>
<td>Kaempferol</td>
<td>0.14</td>
</tr>
<tr>
<td>Isorhamnetin</td>
<td>0.29</td>
</tr>
<tr>
<td>Nicotiflorin</td>
<td>0.05</td>
</tr>
<tr>
<td>Narcissin</td>
<td>1.24</td>
</tr>
</tbody>
</table>
Results
We identified and quantified the major phytochemicals present in 1 g of Dermaval (Table 1). Punicalagins were the most abundant phytochemical present in the sample, at 202.26 mg/g. The next most abundant phytochemicals, chlorogenic acids, quercetin, and ascorbic acid, were an order of magnitude less abundant at 15.51, 13.98, and 8.71 mg/g, respectively. The other components each represented less than 1 mg/g of Dermaval.

The specific activity of HNE is shown in Figure 1. There was no difference in HNE activity among the untreated individuals over the 2 hours of the study. Treatment with glucose significantly increased HNE activity over the initial baseline value at both time points (171%±25% at 60 minutes after glucose ingestion versus baseline, \(P<0.028\); 186%±51% at 120 minutes after glucose ingestion versus baseline, \(P<0.045\)). Participants who consumed Dermaval prior to glucose did not show an increase in HNE activity. Mean HNE activity was 100%±8% and 88%±10% of baseline at 60 and 120 minutes after glucose ingestion, respectively. Treatment with Dermaval prior to glucose resulted in HNE activity similar to that of fasting alone and significantly lower than glucose treatment alone (\(P<0.005\) 60 minutes after glucose ingestion and \(P<0.039\) 120 minutes after glucose ingestion versus glucose only).

Blood glucose levels were measured at all time points in all three experimental groups to ensure that none of the study subjects experienced hypoglycemia after overnight fasting and to verify whether ingestion of Dermaval affected blood glucose levels. As seen in Figure 2, there was no difference in blood glucose levels between the group treated with glucose and the group treated with Dermaval and glucose.

Discussion
We demonstrated that a modest, single dose of glucose can increase HNE activity in humans during the first 60 minutes after ingestion. We then exploited this effect to test putative elastase inhibitors. We report here for the first time that a single 50 mg dose of Dermaval can prevent a glucose-induced increase in HNE activity. Dermaval did not directly affect blood glucose levels.

The inhibitory effect of Dermaval on HNE activity did not correspond to a simultaneous reduction in blood glucose levels under these experimental conditions. It is unclear as to how Dermaval affects HNE activity. Our hypothesis is that this phytochemical preparation indirectly inhibits elastase activity. We are currently testing the hypothesis that Dermaval may affect blood levels of metalloproteinases, tissue inhibitors of metalloproteinases, proinflammatory cytokines, and chemokines under these experimental conditions. If confirmed, Dermaval may contribute to curtailing the proinflammatory state caused by high sugar consumption. Excessive HNE activity is thought to play a role in various pathologic processes.

Increased levels of HNE activity have been measured in pneumonia,\(^{35}\) cystic fibrosis,\(^{36}\) and complications associated with balloon angioplasty.\(^{37}\) A study by Talukdar et al\(^{38}\) showed that neutrophil elastase secreted by neutrophils contributes to insulin resistance induced by a high-fat diet.
HNE inhibition is recognized as an important molecular target for preventing HNE-mediated pathologies and health problems. Several natural nondrug substances have been shown to inhibit HNE activity.

We report that Dermaval possesses acute anti-HNE activity during the first hour after treatment, presumably due to one or more of its constituent phytochemicals. Quercetin, for example, can suppress HNE transcription and expression; however, its role as a direct inhibitor is less clearly understood. A 50 mg dose of Dermaval contains rather low levels of these phytochemicals, yet the current clinical data would suggest that it potently modulates HNE activity. It is conceivable that more than one constituent possesses anti-HNE activity or that the constituents work together synergistically.

In summary, a single 50 mg dose of Dermaval was shown to inhibit glucose-induced HNE activity in human healthy subjects. Further investigations are needed to verify whether Dermaval inhibits HNE activity directly or indirectly. In addition, the results justify testing of Dermaval for skin health following treatment over a longer period of time.

Acknowledgments

We express our gratitude to John Hunter and Brad Evers (FutureCeuticals Inc.) for their comments and suggestions in the preparation of this paper. We would like to thank Michael Sapko for his help in editing the manuscript.

Disclosure

This study was funded by FutureCeuticals Inc. The authors report no other conflicts of interest in this work.

References


